Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director departure
CODEXIS, INC. (CDXS) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/03/2023 8-K Quarterly results
Docs: "Codexis Reports Second Quarter 2023 Financial Results Company Recently Announced Enhanced Strategic Focus and Portfolio Prioritization"
02/23/2023 8-K Quarterly results
Docs: "Codexis Reports Fourth Quarter and Fiscal Year 2022 Financial Results Biotherapeutics Application of CodeEvolver® Validated by Recent Data Supporting the Potential for Three Upcoming Investigational New Drug Applications"
08/04/2022 8-K Quarterly results
Docs: "Codexis Reports Second Quarter 2022 Financial Results Total Revenue up 51% and Product Revenue up 135% YOY 2022 Total Revenue Guidance of $135M-$141M, Including Product Revenues of $112M-$118M Codexis Reports Second Quarter 2022 Financial Results"
05/05/2022 8-K Quarterly results
02/24/2022 8-K Quarterly results
11/04/2021 8-K Quarterly results
Docs: "Codexis Reports Third Quarter 2021 Financial Results Record Quarterly Total Revenue, Product Revenue and Product Gross Margin Reiterating Total Revenue Guidance of $98-103M&#59; Raising Product Revenue Guidance to $63-66M"
08/05/2021 8-K Quarterly results
Docs: "Codexis Reports Second Quarter 2021 Financial Results Record Product Revenue of $14.7M, up 227% YOY Record Product Gross Margin of 71% Codexis Reports Second Quarter 2021 Financial Results Record Product Revenue of $14.7M, up 227% YOY"
02/25/2021 8-K Quarterly results
11/05/2020 8-K Quarterly results
Docs: "Codexis Reports Third Quarter 2020 Financial Results Stronger than expected total revenues of $18.4 million delivered in the quarter Higher sequential sales expected again in the fourth quarter, showing growing momentum as we close 2020"
08/06/2020 8-K Quarterly results
05/07/2020 8-K Quarterly results
02/27/2020 8-K Quarterly results
11/05/2019 8-K Quarterly results
Docs: "Codexis, Inc. Condensed Consolidated Statements of Operations"
08/06/2019 8-K Quarterly results
05/06/2019 8-K Quarterly results
Docs: "Codexis, Inc. Condensed Consolidated Statements of Operations"
02/26/2019 8-K Quarterly results
11/08/2018 8-K Quarterly results
Docs: "Codexis, Inc. Condensed Consolidated Statements of Operations"
08/08/2018 8-K Quarterly results
Docs: "Codexis, Inc. Condensed Consolidated Statements of Operations"
05/10/2018 8-K Quarterly results
Docs: "Codexis Reports First Quarter 2018 Financial Results Total revenues increase 76% to $14.0 million on sharply higher R&D revenue Conference call begins at 4:30 p.m. Eastern time today REDWOOD CITY, Calif. - Codexis, Inc. , a leading protein engineering company, announces financial results for the three months ended March 31, 2018 and provides a business update. “We began the year with strong first quarter revenues of $14 million, a 76% increase over the prior-year period,” said Codexis President and CEO John Nicols. “That growth was driven by a 230% increase in R&D revenue with major contributions from our marquis customers Nestlé Health Science, Merck, Tate & Lyle and another global pharmaceutical customer. “We also are off to an excellent start so far this year in delivering against the c..."
03/08/2018 8-K Quarterly results
Docs: "Codexis Reports 2017 Fourth Quarter and Full Year Financial Results 2017 revenues of $50 million include a 74% increase in product sales Introduces 2018 financial guidance Conference call begins at 4:30 pm Eastern time today Accompanying slide presentation available on Investor section of company website REDWOOD CITY, Calif. - Codexis, Inc. , a leading protein engineering company, announces financial results for the three and 12 months ended December 31, 2017, provides a business update and introduces 2018 financial guidance. “We closed out an exceptional year with fourth quarter revenues exceeding $21 million, more than double third quarter revenues,” said Codexis President and CEO John Nicols. “Revenues for 2017 of $50 million increased slightly over 2016 and met our annual guidance as w..."
11/09/2017 8-K Quarterly results
Docs: "Codexis Reports Financial Results for the Third Quarter of 2017 Product sales increase 71% over the prior year Affirms 2017 revenue guidance Conference call begins at 4:30 pm Eastern time today REDWOOD CITY, Calif. - Codexis, Inc. , a leading protein engineering company, announces financial results for the three and nine months ended September 30, 2017, and provides a business update. “We continue to deliver excellent results in 2017, highlighted by the creation of our new partnership with Nestlé Health Science, as well as a solid financial performance,” said Codexis President and CEO John Nicols. “Our recently announced strategic collaboration with Nestlé Health Science validates the use of our CodeEvolver ® protein engineering technology platform for biotherapeutic drug discovery and dem..."
08/09/2017 8-K Quarterly results
05/09/2017 8-K Form 8-K - Current report
03/09/2017 8-K Form 8-K - Current report
11/08/2016 8-K Quarterly results
Docs: "Codexis Reports Financial Results for the Third Quarter of 2016 Revenues of $14.9 million driven by core biocatalyst product sales increase of 123% and include $8.0 million milestone revenue from Merck Conference call begins at 4:30 p.m. Eastern time today REDWOOD CITY, Calif. - Codexis, Inc. , a leading protein engineering company, announces financial results for the three and nine months ended September 30, 2016, and provides a business update. “Our exceptional third quarter financial results feature revenues of $14.9 million and I’m pleased to report that $4.1 million came from product revenues,” said Codexis President and CEO John Nicols. “Through the first nine months of 2016, product revenues have grown by over 60% versus the same period last year, highlighting the growing momentum o..."
08/09/2016 8-K Quarterly results
Docs: "Codexis Reports Financial Results for the Second Quarter of 2016 Net income reaches $2.2 million; revenues of $16.0 million include milestone payments from GSK and a major biopharmaceutical company, and 62% growth in core biocatalyst product sales Conference call begins at 4:30 p.m. Eastern time today REDWOOD CITY, Calif. - Codexis, Inc. , a leading protein engineering company, announces financial results for the three and six months ended June 30, 2016, and provides a business update. “We are reporting outstanding financial results for the second quarter, with $2.2 million in net income on total revenues of $16.0 million and a strong operating performance,” said Codexis President and CEO John Nicols. “Revenues for the quarter reflect the successful completion of our CodeEvolver ® protein ..."
05/09/2016 8-K Form 8-K - Current report
03/03/2016 8-K Quarterly results
Docs: "Codexis, Inc. Condensed Consolidated Statements of Operations"
11/04/2015 8-K Quarterly results
Docs: "Codexis, Inc. Condensed Consolidated Statements of Operations"
08/11/2015 8-K Quarterly results
Docs: "Codexis, Inc. Condensed Consolidated Statements of Operations"
05/07/2015 8-K Quarterly results
Docs: "Codexis, Inc. Condensed Consolidated Statements of Operations"
03/03/2015 8-K Quarterly results
Docs: "Codexis, Inc. Consolidated Statements of Operations"
11/04/2014 8-K Quarterly results
Docs: "Codexis Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2014 -- Conference call today at 4:30 pm ET --"
08/06/2014 8-K Quarterly results
Docs: "EXHIBIT"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy